Characteristics of Patients Participating in the Study (N = 50)
| Characteristics | Value |
|---|---|
| Demographics | |
| Age, years, mean (range) | 69.0 (42.0 to 94.0) |
| Sex, n (%) | |
| Male | 27 (54.0) |
| Female | 23 (46.0) |
| Ethnicity, n (%) | |
| White or Caucasian | 42 (84.0) |
| Hispanic or Latino | 2 (4.0) |
| Other or unspecified | 6 (12.0) |
| Most frequent diagnoses, n (%)* | |
| Hyperlipidemia | 38 (76.0) |
| Hypertension | 38 (76.0) |
| Type 2 diabetes mellitus | 23 (46.0) |
| Hypothyroidism | 16 (32.0) |
| Vitamin D deficiency | 16 (32.0) |
| Allergic rhinitis | 11 (22.0) |
| Anxiety | 10 (20.0) |
| Gastroesophageal reflux disorder | 10 (20.0) |
| Major depressive disorder | 8 (16.0) |
| Insomnia | 7 (14.0) |
| Medications | |
| Number, mean (± SD)† | |
| Total medications | 12.1 (± 4.6) |
| Chronic medications | 10.4 (± 4.3) |
| Medication risk mitigation–associated factors | |
| Cognitive burden risk score | 2.0 (± 1.7) |
| Falls risk score | 5.5 (± 4.0) |
| Number of PIMs | 1.4 (± 1.2) |
| Creatinine clearance (mL/min) | 66.2 (± 20.8) |
| Heart rhythm risk score | 3.6 (± 3.6) |
| Most frequently prescribed, n (%)‡ | |
| Aspirin | 25 (50.0) |
| Vitamin D | 24 (48.0) |
| Atorvastatin | 23 (46.0) |
| Levothyroxine | 17 (34.0) |
| Omega-3 fatty acids | 14 (28.0) |
| Amlodipine | 13 (26.0) |
| Esomeprazole | 11 (22.0) |
| Clopidogrel | 8 (16.0) |
| Metoprolol succinate | 8 (16.0) |
| Omeprazole | 8 (16.0) |
↵* As reported in the patient’s chart. Percentage out of total patients included.
↵† As determined by the pharmacist’s medication reconciliation process.
↵‡ As determined by the pharmacist’s medication reconciliation process. Percentage out of total patients included.
Abbreviations: PIM, potentially inappropriate medication; SD, standard deviation.